Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib by Eberhard David A, Johnson Bruce E, Amler Lukas C, Goddard Audrey D, Heldens Sherry L, Herbst Roy S, Ince William L, Jänne Pasi A, Januario Thomas, Johnson David H, Klein Pam, Miller Vincent A, Ostland Michael A, Ramies David A, Sebisanovic Dragan, Stinson Jeremy A, Zhang Yu R, Seshagiri Somasekar, Hillan Kenneth J in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2005).

[PMID: 16043828] PubMed


Epidermal growth factor receptor (EGFR) mutations have been associated with tumor response to treatment with single-agent EGFR inhibitors in patients with relapsed non-small-cell lung cancer (NSCLC). The implications of EGFR mutations in patients treated with EGFR inhibitors plus first-line chemotherapy are unknown. KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Dosing Information

No dosing information annotated.